Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer
This is a phase â…¡ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer.
Pancreatic Cancer
DRUG: gemcitabine and cisplatin
recurrence/metastasis free survival, 24 months
2 year survival rate, 24 months|Overall survival, 24 months|recurrence free survival, Median recurrence free survival time, 24 months|Safety and tolerability, patients who experienced grade 3-4 toxicity by RECIST criteria, 24 months
The primary study objective is to evaluate recurrence/metastasis free survival at 12 months with postoperative adjuvant treatment incorporating gemcitabine plus cisplatin chemotherapy followed by chemoradiation with gemcitabine followed by maintenance chemotherapy with gemcitabine.